Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

Armstrong AW(2017)From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis J Am Acad Dermatol 76 290-298

Siegel MP(2017)Treating psoriasis and psoriatic arthritis: position paper on applying the treat-to-target concept to Canadian daily practice J Rheumatol 44 519-534

Bagel J(2020)Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) Br J Dermatol 182 1158-1166

Boh EE(2021)Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations Dermatol Ther (Heidelb) 11 235-252

Buell M(2014)Eliciting preferences to inform patient-centred policies: the case of psoriasis Pharmacoeconomics 32 209-223

Cooper KD(2016)Patient-relevant treatment goals in psoriasis Arch Dermatol Res 308 69-78

Gladman DD(2018)Pathogenesis of psoriasis and development of treatment J Dermatol 45 264-272

Poulin Y(2015)Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Lancet 386 541-551

Adams K(2017)Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study Br J Dermatol 177 1014-1023

Bourcier M(2019)Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study J Am Acad Dermatol 80 70-79

Armstrong AW(2017)From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis J Am Acad Dermatol 76 290-298

Siegel MP(2017)Treating psoriasis and psoriatic arthritis: position paper on applying the treat-to-target concept to Canadian daily practice J Rheumatol 44 519-534

Bagel J(2020)Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) Br J Dermatol 182 1158-1166

Boh EE(2021)Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations Dermatol Ther (Heidelb) 11 235-252

Buell M(2014)Eliciting preferences to inform patient-centred policies: the case of psoriasis Pharmacoeconomics 32 209-223

Cooper KD(2016)Patient-relevant treatment goals in psoriasis Arch Dermatol Res 308 69-78

Gladman DD(2018)Pathogenesis of psoriasis and development of treatment J Dermatol 45 264-272

Poulin Y(2015)Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Lancet 386 541-551

Adams K(2017)Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study Br J Dermatol 177 1014-1023

Bourcier M(2019)Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study J Am Acad Dermatol 80 70-79